The molecular reach of antibodies crucially underpins their viral neutralisation capacity
Huhn A. et al, (2025), Nature Communications, 16
Concerted deletions eliminate a neutralizing supersite in SARS-CoV-2 BA.2.87.1 spike.
Duyvesteyn HME. et al, (2024), Structure (London, England : 1993), 32, 1594 - 1602.e6
Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: A prospective observational study in Vietnam
Thanh TT. et al, (2024), International Journal of Infectious Diseases, 147, 107173 - 107173
Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition
Asor R. et al, (2024), Proceedings of the National Academy of Sciences, 121
A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity
Liu C. et al, (2024), Cell Reports Medicine, 5, 101553 - 101553
Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection.
Liu C. et al, (2024), Nature communications, 15
The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86.
Zhou D. et al, (2024), Nature communications, 15
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
Dijokaite-Guraliuc A. et al, (2023), Cell Reports, 42, 112271 - 112271
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
Huo J. et al, (2023), Cell Reports, 42, 111903 - 111903
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
The antigenic anatomy of SARS-CoV-2 receptor binding domain
Dejnirattisai W. et al, (2021), Cell, 184, 2183 - 2200.e22
Flavivirus maturation leads to the formation of an occupied lipid pocket in the surface glycoproteins
Renner M. et al, (2021), Nature Communications, 12
Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020
Thompson CP. et al, (2020), EUROSURVEILLANCE, 25, 33 - 41
Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice.
Salazar V. et al, (2019), Cell reports, 26, 1585 - 1597.e4
Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine
Tsai W-Y. et al, (2018), Journal of Virology, 92
Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus
Renner M. et al, (2018), Nature Immunology, 19, 1248 - 1256
The immune response against flaviviruses
Slon Campos JL. et al, (2018), Nature Immunology, 19, 1189 - 1198
Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas
Montoya M. et al, (2018), The Journal of Infectious Diseases, 218, 536 - 545